Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy With BCG Plus a Polyvalent Melanoma Vaccine, CancerVax™ Vaccine Versus BCG Plus a Placebo as a Post-Surgical Treatment for Stage III Melanoma

NCT00052130 is registered in ClinicalTrials.gov with CancerVax Corporation as lead sponsor.

NCT NCT00052130
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00052130 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy With BCG Plus a Polyvalent Melanoma Vaccine, CancerVax™ Vaccine Versus BCG Plus a Placebo as a Post-Surgical Treatment for Stage III Melanoma
Lead sponsor
CancerVax Corporation
Phase
Phase 3
Overall status
Unknown status
Start date
Not reported
Completion date
Not reported
Enrollment
1,118
Sites
80

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma